Caroline Palomeque
Stock Analyst at Maxim Group
(2.59)
# 2,174
Out of 4,670 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $3.34 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $34.07 | +73.17% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $190.40 | -19.12% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $49.00 | +18.37% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $129.81 | +27.88% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $24.69 | +57.96% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $9.59 | +536.08% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $9.11 | +339.08% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.34
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $34.07
Upside: +73.17%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $190.40
Upside: -19.12%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $49.00
Upside: +18.37%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $129.81
Upside: +27.88%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $24.69
Upside: +57.96%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $9.59
Upside: +536.08%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $9.11
Upside: +339.08%